Strengthening Manufacturing Technology Capabilities through R&D, Capital Investment and Talent Development
First written in FY2016. 22 of 30 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026The company continued its R&D activities and disclosed annual R&D expenses.Annual report
「As a result of these activities, R&D expenses for the consolidated fiscal year amounted to ¥198.512 million.」
The company continues R&D aimed at commercialising its proprietary technologies and disclosed R&D expenses of ¥198.512 million for the consolidated fiscal year. - 2026-08-10RestatedRevisions to earnings forecasts
「Within the Group, we worked to improve and maintain stable quality and enhance production efficiency, while advancing technological development with a view to entering new business areas.」
The Company continues to improve quality and production efficiency and pursue technological development with a view to entering new business areas. - FY2025AdvancedAnnual report
「As a result of these activities, R&D expenses for the fiscal year were ¥303.178 million.」
Continues R&D aimed at commercialising proprietary technologies, with R&D expenses increasing from ¥127.769 million in the previous fiscal year to ¥303.178 million. - FY2025-H1AdvancedAnnual report
「Against this backdrop, the Group strategically pursued entry into new business areas and research and development of new technologies, while making active investments in personnel and equipment to maintain the high quality of existing products. The amount spent on R&D activities by the Group as a whole during the interim consolidated accounting period was ¥75 million.」
In addition to new business areas and technology R&D, the company invested in personnel and equipment, and disclosed interim-period R&D expenses of ¥75 million. - FY2024AdvancedAnnual report
「In machinery and equipment, we enhanced the functionality of dispenser equipment. As a result, research and development expenses related to machinery and equipment amounted to ¥72.428 million. In dies, we conducted die-technology development for high-performance drawn components and fine-pin components. As a result, research and development expenses related to dies amounted to ¥55.340 million. As a result of these activities, research and development expenses for the consolidated fiscal year amounted to ¥127.769 million.」
Continues strengthening its manufacturing technology through R&D and provides detailed disclosure of R&D activities by machinery and equipment and molds, with total R&D expenses of ¥127.769 million. - FY2024-Q3RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative third quarter was ¥89 million. There were no material changes in the Group's R&D activities during the cumulative third quarter.」
Discloses cumulative third-quarter R&D expenses of ¥89 million and states that there were no material changes in R&D activities. - FY2024-Q2RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative second quarter was ¥61 million. There were no material changes in the Group's R&D activities during the cumulative second quarter.」
Discloses cumulative second-quarter R&D expenses of ¥61 million and states that there were no material changes in R&D activities. - FY2024-Q1RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative first quarter was ¥30 million. There were no material changes in the Group's R&D activities during the cumulative first quarter.」
Discloses first-quarter R&D expenses of ¥30 million and states that there were no material changes in R&D activities. - FY2023AdvancedAnnual report
「As a result of these activities, R&D expenses for the fiscal year were ¥104.051 million.」
Continues R&D activities and discloses R&D expenses of ¥104.051 million for the fiscal year ended June 2023. - FY2023-Q3RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative third quarter was ¥79 million. There were no material changes in the Group's R&D activities during the cumulative third quarter.」
Discloses cumulative third-quarter R&D expenses of ¥79 million and states that there were no material changes in R&D activities. - FY2022-Q3RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative third quarter was ¥76 million. There were no material changes in the Group's R&D activities during the cumulative third quarter.」
Discloses cumulative third-quarter R&D expenses of ¥76 million and states that there were no material changes in R&D activities. - FY2022-Q2RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative second quarter was ¥57 million. There were no material changes in the Group's R&D activities during the cumulative second quarter.」
Discloses cumulative second-quarter R&D expenses of ¥57 million and states that there were no material changes in R&D activities. - FY2022-Q1RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative first quarter was ¥39 million. There were no material changes in the Group's R&D activities during the cumulative first quarter.」
Discloses cumulative first-quarter R&D expenses of ¥39 million and states that there were no material changes in R&D activities. - FY2021-Q3RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative third quarter was ¥104 million. There were no material changes in the Group's R&D activities during the cumulative third quarter.」
Discloses cumulative third-quarter R&D expenses of ¥104 million and states that there were no material changes in R&D activities. - FY2021-Q2RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative second quarter was ¥67 million. There were no material changes in the Group's R&D activities during the cumulative second quarter.」
Discloses cumulative second-quarter R&D expenses of ¥67 million and states that there were no material changes in R&D activities. - FY2021-Q1RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative first quarter was ¥26 million. There were no material changes in the Group's R&D activities during the cumulative first quarter.」
Discloses cumulative first-quarter R&D expenses of ¥26 million and states that there were no material changes in R&D activities. - FY2020RestatedAnnual report
「As a result of these activities, R&D expenses for the fiscal year were ¥121.456 million.」
Continues R&D aimed at commercialising proprietary technologies and discloses R&D expenses of ¥121.456 million for the fiscal year ended June 2020. - FY2020-Q3RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative third quarter was ¥96 million. There were no material changes in the Group's R&D activities during the cumulative third quarter.」
Discloses cumulative third-quarter R&D expenses of ¥96 million and states that there were no material changes in R&D activities. - FY2020-Q2RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative second quarter was ¥72 million. There were no material changes in the Group's R&D activities during the cumulative second quarter.」
Discloses cumulative second-quarter R&D expenses of ¥72 million and states that there were no material changes in R&D activities. - FY2020-Q1RestatedAnnual report
「The amount spent on R&D activities by the Group as a whole during the cumulative first quarter was ¥46 million. There were no material changes in the Group's R&D activities during the cumulative first quarter.」
Discloses cumulative first-quarter R&D expenses of ¥46 million and states that there were no material changes in R&D activities. - FY2019AdvancedAnnual report
「In machinery and equipment, we focused on developing LED flip-chip mounting equipment incorporating new mounting technology and worked toward its launch into mass production. We also worked on developing automated medical equipment, among other initiatives. As a result, research and development expenses related to machinery and equipment amounted to ¥140.277 million. In dies, we conducted technology development for press processing of new materials and for improving wear resistance in die materials. As a result, research and development expenses related to dies amounted to ¥6.751 million. As a result of these activities, research and development expenses for the consolidated fiscal year amounted to ¥147.028 million.」
Identifies LED flip-chip mounting equipment, medical automation equipment, and research and development into new-material processing and wear improvement as R&D targets, and discloses annual R&D expenses of ¥147.028 million. - FY2019-Q3RestatedAnnual report
「The amount spent on research and development activities by our Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥102 million. There were no material changes in the status of our Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company disclosed research and development expenses of ¥102 million for the cumulative third quarter and stated that there had been no material changes in its research and development activities. - FY2019-Q2RestatedAnnual report
「The amount spent on research and development activities by our Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥69 million. There were no material changes in the status of our Group's research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
The company disclosed research and development expenses of ¥69 million for the cumulative second quarter and stated that there had been no material changes in its research and development activities. - FY2019-Q1RestatedAnnual report
「The amount spent on research and development activities by our Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥32 million. There were no material changes in the status of our Group's research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The company disclosed research and development expenses of ¥32 million for the cumulative first quarter and stated that there had been no material changes in its research and development activities. - FY2018AdvancedAnnual report
「In addition to the above, we conducted research into basic technologies. As a result of these activities, research and development expenses for the consolidated fiscal year amounted to ¥134 million.」
The company identified research and development activities covering manufacturing methods for die components, press-material feeding equipment, automated-machine development, prototyping and evaluation, and disclosed annual research and development expenses of ¥134 million. - FY2018-Q3RestatedAnnual report
「The amount spent on research and development activities by our Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥100 million. There were no material changes in the status of our Group's research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company disclosed research and development expenses of ¥100 million for the cumulative third quarter and stated that there had been no material changes in its research and development activities. - FY2017-Q3RestatedAnnual report
「We will continue to carry out planned research and development, capital investment and human-resource development to establish this framework, and strengthen our corporate foundation under a flexible management strategy.」
The company has reiterated its policy of continuing research and development, capital investment and human-resource development to strengthen its corporate foundation. - FY2017-Q2RestatedAnnual report
「We will continue to carry out planned research and development, capital investment and human-resource development to establish this framework, and strengthen our corporate foundation under a flexible management strategy.」
The company has reiterated its policy of continuing research and development, capital investment and human-resource development to strengthen its manufacturing and technology framework and corporate foundation. - FY2017-Q1RestatedAnnual report
「We will continue to carry out planned research and development, capital investment and human-resource development to establish this framework, and strengthen our corporate foundation by enhancing our manufacturing expertise.」
The company has reiterated its policy of continuing research and development, capital investment and human-resource development to strengthen its manufacturing expertise. - FY2016First statedAnnual report
「We will continue to carry out planned research and development, capital investment and human-resource development to establish this framework, and strengthen our corporate foundation by enhancing our manufacturing expertise.」
The company has set out a policy of continuing research and development, capital investment and human-resource development as an integrated program.